日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms

骨髓增生异常肿瘤患者生活质量评估量表（QOL-E）的心理测量学特性和有意义的变化阈值

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2025.1507854
Oliva, Esther Natalie; Guo, Shien; Lord-Bessen, Jennifer; Yucel, Aylin; Latagliata, Roberto; Breccia, Massimo; Palumbo, Giuseppe A; Sanpaolo, Grazia; Riva, Marta; Santini, Valeria; Platzbecker, Uwe; Garcia-Manero, Guillermo; Fenaux, Pierre; Pelligra, Christopher G
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial

确定 NTDT-PRO 评分改善的阈值，以支持对非输血依赖型 β-地中海贫血患者临床研究中治疗获益的结论：一项 2 期双盲、安慰剂对照、随机试验的汇总数据分析

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2024-085234
Taher, Ali T; Musallam, Khaled M; Viprakasit, Vip; Kattamis, Antonis; Lord-Bessen, Jennifer; Yucel, Aylin; Guo, Shien; Pelligra, Christopher G; Shields, Alan L; Shetty, Jeevan K; Glassberg, Mrudula B; Bueno, Luciana Moro; Cappellini, Maria Domenica
贫血
代谢
发表日期：2024
文献求助 收藏

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

埃洛妥珠单抗联合泊马度胺/地塞米松治疗复发/难治性多发性骨髓瘤患者对健康相关生活质量的影响：来自 2 期 ELOQUENT-3 试验的最终数据

期刊:Hemasphere
影响因子:14.6
doi:10.1097/HS9.0000000000000843
Weisel, Katja; Dimopoulos, Meletios A; San-Miguel, Jesús; Paner, Agne; Engelhardt, Monika; Taylor, Fiona; Lord-Bessen, Jennifer; Yip, Christine; Greenwood, Mike; Tang, Jackson; Cavo, Michele
多发性骨髓瘤
NT-3
骨髓瘤
发表日期：2023
文献求助 收藏

Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials

评估开放标签设计对患者报告结局的影响：肿瘤临床试验研究

期刊:JNCI Cancer Spectrum
影响因子:4.1
doi:10.1093/jncics/pkad002
Lord-Bessen, Jennifer; Signorovitch, James; Yang, Min; Georgieva, Mihaela; Roydhouse, Jessica
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia

对 NTDT-PRO 问卷进行心理测量学评价，以评估非输血依赖型 β-地中海贫血患者的症状。

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2022-066683
Taher, Ali T; Musallam, Khaled M; Viprakasit, Vip; Kattamis, Antonis; Lord-Bessen, Jennifer; Yucel, Aylin; Guo, Shien; Pelligra, Christopher; Shields, Alan L; Shetty, Jeevan K; Miteva, Dimana; Bueno, Luciana Moro; Cappellini, Maria Domenica
代谢
贫血
发表日期：2023
文献求助 收藏

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY

P935：LOCOMOTION 研究中 TECLISTAMAB 与现有疗法在接受过三类药物治疗的复发/难治性多发性骨髓瘤患者中的疗效真实世界比较分析

期刊:Applied and Environmental Microbiology
影响因子:3.7
doi:10.1128/AEM.65.11.5082-5088.1999
van Schie, P M; Fletcher, M; van de Donk, N W; Guo, S; Shi, L; Lord-Bessen, J; Tang, D; Karlin, L; Weisel, K; Ramasamy, K; Abad, P C; Amin, A; Amin, S; Lonial, S; Einsele, H; Moreau, P; Delforge, M; van de Donk, N W; Ghilotti, F; Diels, J; Elsada, A; Strulev, V; Pei, L; Kobos, R; Smit, J; Slavcev, M; Weisel, K; Mateos, M-V
多发性骨髓瘤
TEC
骨髓瘤
发表日期：2022
文献求助 收藏

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Fedratinib 可改善既往接受过 Ruxolitinib 治疗的骨髓纤维化患者的骨髓纤维化相关症状和健康相关生活质量：来自 II 期 JAKARTA2 试验的患者报告结果

期刊:Hemasphere
影响因子:14.6
doi:10.1097/HS9.0000000000000562
Harrison, Claire N; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Jourdan, Eric; Silver, Richard T; Schouten, Harry C; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Tang, Derek; Abraham, Pranav; Lord-Bessen, Jennifer; Rose, Shelonitda; Guo, Shien; Liao, Weiqin; Mesa, Ruben A
JAK/STAT
发表日期：2021
文献求助 收藏

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

在随机、安慰剂对照的 III 期 JAKARTA 试验中，口服选择性 Janus 激酶 2 抑制剂 Fedratinib 对骨髓纤维化相关症状和健康相关生活质量的患者报告效应

期刊:Hemasphere
影响因子:14.6
doi:10.1097/HS9.0000000000000553
Mesa, Ruben A; Schaap, Nicolaas; Vannucchi, Alessandro M; Kiladjian, Jean-Jacques; Passamonti, Francesco; Zweegman, Sonja; Talpaz, Moshe; Verstovsek, Srdan; Rose, Shelonitda; Abraham, Pranav; Lord-Bessen, Jennifer; Tang, Derek; Guo, Shien; Ye, Xiaomei; Harrison, Claire N
JAK/STAT
信号转导
发表日期：2021
文献求助 收藏

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

伊匹木单抗和非伊匹木单抗疗法治疗晚期黑色素瘤的长期真实世界经验：IMAGE 研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-021-08032-y
Dalle, Stéphane; Mortier, Laurent; Corrie, Pippa; Lotem, Michal; Board, Ruth; Arance, Ana María; Meiss, Frank; Terheyden, Patrick; Gutzmer, Ralf; Buysse, Brian; Oh, Kelly; Brokaw, Jane; Le, T Kim; Mathias, Susan D; Scotto, Julie; Lord-Bessen, Jennifer; Moshyk, Andriy; Kotapati, Srividya; Middleton, Mark R
黑色素瘤
MAG
发表日期：2021
文献求助 收藏

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial

MEDALIST 3期试验中，接受Luspatercept治疗的伴有环状铁粒幼细胞的骨髓增生异常综合征患者的健康相关生活质量结果

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm11010027
Oliva, Esther Natalie; Platzbecker, Uwe; Garcia-Manero, Guillermo; Mufti, Ghulam J; Santini, Valeria; Sekeres, Mikkael A; Komrokji, Rami S; Shetty, Jeevan K; Tang, Derek; Guo, Shien; Liao, Weiqin; Zhang, George; Ha, Xianwei; Ito, Rodrigo; Lord-Bessen, Jennifer; Backstrom, Jay T; Fenaux, Pierre
细胞生物学
发表日期：2021
文献求助 收藏